Loading...
XSTO
SOBI
Market cap12bUSD
Dec 04, Last price  
343.00SEK
1D
4.26%
1Q
24.19%
Jan 2017
221.46%
IPO
574.48%
Name

Swedish Orphan Biovitrum AB (publ)

Chart & Performance

D1W1MN
XSTO:SOBI chart
P/E
30.43
P/S
4.54
EPS
11.27
Div Yield, %
—
Shrs. gr., 5y
2.30%
Rev. gr., 5y
12.81%
Revenues
26.03b
+17.65%
936,611,0001,201,099,0001,256,425,0001,140,583,0001,296,973,0001,906,700,0001,910,834,0001,923,161,0002,176,694,0002,606,976,0003,227,867,0005,204,340,0006,510,831,0009,138,892,00014,248,000,00015,261,000,00015,529,000,00018,790,000,00022,123,000,00026,027,000,000
Net income
3.89b
+61.27%
176,221,00092,668,00078,984,000-335,361,00032,437,000-104,400,00017,927,000-100,883,000-92,956,000-267,832,00068,393,000809,072,0001,148,612,0002,417,795,0003,304,000,0003,245,000,0002,679,000,0002,638,000,0002,409,000,0003,885,000,000
CFO
7.39b
+65.28%
-65,321,000-87,958,000-25,373,000-506,489,00058,885,000-215,100,000102,930,000405,473,000185,389,000233,770,000507,205,000342,857,0001,332,942,0002,090,276,0003,634,000,0005,214,000,0005,470,000,0004,665,000,0004,470,000,0007,388,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
URL
https://www.sobi.com/
IPO date
Sep 15, 2006
Employees
1,793
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT